# 3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis

> **NCT04931667** · PHASE3 · TERMINATED · sponsor: **Biosplice Therapeutics, Inc.** · enrollment: 72 (actual)

## Conditions studied

- Osteoarthritis of the Knee

## Interventions

- **DRUG:** Lorecivivint

## Key facts

- **NCT ID:** NCT04931667
- **Lead sponsor:** Biosplice Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-15
- **Primary completion:** 2021-12-13
- **Final completion:** 2021-12-13
- **Target enrollment:** 72 (ACTUAL)
- **Why stopped:** Study was terminated by Sponsor based on a business decision not due to safety. The study report was finalized without any statistical analysis.
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04931667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04931667, "3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04931667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*